AstraZeneca, Dynavax amend agreement to accelerate development of asthma drug – Proactive Investors USA & Canada


Proactive Investors USA & Canada

AstraZeneca, Dynavax amend agreement to accelerate development of asthma drug
Proactive Investors USA & Canada
AstraZeneca (NYSE:AZN) and Dynavax Technologies (NASDAQ:DVAX) announced Wednesday they have amended their collaboration agreement so as to accelerate the development of AZD1419, intended for the treatment of asthma. Under the terms of the agreement,
Dynavax and AstraZeneca to Advance TLR-9 Agonist Into Clinic for AsthmaMarketWatch (press release)
Dynavax gets $3M in reworked asthma deal with AstraZenecaBizjournals.com (blog)

all 12 news articles »

View full post on asthma – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.